Related Experiment Videos
Tumor lysis syndrome
1Department of Pediatrics, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Seminars in Hematology
|November 6, 2001
Summary
Tumor lysis syndrome (TLS) is a metabolic complication of cancer treatment, causing dangerous electrolyte imbalances and kidney damage. Novel treatments like urate oxidase offer effective management with a good safety profile.
Area of Science:
- Oncology
- Nephrology
- Metabolic Disorders
Background:
- Tumor lysis syndrome (TLS) is a critical condition characterized by metabolic disturbances due to high tumor cell turnover.
- It results from the release of intracellular contents (uric acid, potassium, phosphorus), overwhelming clearance mechanisms.
- TLS is often triggered by chemotherapy but can occur spontaneously, leading to significant morbidity and mortality.
Purpose of the Study:
- To review the pathophysiology and management of tumor lysis syndrome.
- To highlight the challenges in preventing and treating TLS-associated acute kidney injury.
- To introduce novel therapeutic approaches for TLS.
Main Methods:
- Literature review of TLS pathophysiology, risk factors, and treatment strategies.
- Analysis of the mechanisms leading to TLS-associated acute renal failure.
- Evaluation of current and emerging management options, including urate oxidase.
Main Results:
- TLS causes hyperuricemia, hyperkalemia, and hyperphosphatemia, often leading to renal compromise.
- Standard prophylaxis (allopurinol, hydration) has limitations and potential adverse effects.
- Urate oxidase demonstrates efficacy and an acceptable safety profile for TLS management.
Conclusions:
- TLS poses a significant risk of acute kidney injury due to multifactorial causes.
- Existing treatments have limitations, necessitating exploration of new therapeutic avenues.
- Urate oxidase represents a promising novel approach for effective TLS treatment.